RIO DE JANEIRO - Johnson & Johnson (NYSE:JNJ) has released updated results from the Phase 1b RedirecTT-1 study, which show promising efficacy and a manageable safety profile for a novel bispecific antibody combination therapy in treating relapsed or refractory multiple myeloma (RRMM). These findings were presented at the International Myeloma Society Annual Meeting.
The study evaluated the combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) in patients who were triple-class exposed, including those with extramedullary disease, which is resistant to standard therapies. The overall response rate (ORR) was 79.5 percent, with a complete response rate of 52.3 percent, and an 18-month progression-free survival rate of 69.8 percent after a median follow-up of 18.2 months.
Subgroup analysis for patients with extramedullary disease showed an ORR of 61.1 percent and an 18-month duration of response of 81.8 percent. The safety profile of the combination therapy was consistent with the profiles of each agent as monotherapy, with cumulative incidence of Grade 3/4 infections slightly higher but plateauing from six months.
The combination therapy is an off-the-shelf option for patients with advanced multiple myeloma, potentially addressing a significant unmet medical need. The results reflect the combinability of TALVEY with other effective therapies, as additional data from the TRIMM-2 study will also be presented at the IMS meeting.
Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow and is considered incurable. It is the second most common blood cancer worldwide, with an estimated 35,000 new cases in the U.S. in 2024. TALVEY® and TECVAYLI® have previously received FDA approval as monotherapies for the treatment of adult patients with RRMM who have received at least four prior lines of therapy.
This article is based on a press release statement and aims to provide investors with a concise summary of the newsworthy facts.
In other recent news, Johnson & Johnson reported encouraging results from a Phase 1b study, TRIMM-2, for patients with relapsed or refractory multiple myeloma. The combination treatment demonstrated an overall response rate of 82 percent. In another development, Johnson & Johnson's subsidiary, Red River Talc LLC, filed for a prepackaged Chapter 11 bankruptcy as part of an $8 billion settlement strategy to resolve ongoing ovarian cancer claims related to cosmetic talc litigation in the U.S.
In legal news, an Oregon judge ordered a new trial in a case involving a $260 million verdict against Johnson & Johnson concerning claims that its talc powder caused mesothelioma. On the financial front, Goldman Sachs reiterated its Buy rating on shares of CG Oncology, citing limited downside risk following new data presented by Johnson & Johnson.
The company also announced significant findings from their Phase 2 SKIPPirr study, indicating a substantial reduction in infusion-related reactions in patients with advanced non-small cell lung cancer treated with RYBREVANT®. Lastly, Johnson & Johnson announced the retirement of D. S. Davis from its board of directors and the retirement of Executive Vice President and Chief Human Resources Officer, Dr. Peter M. Fasolo, with Kristen Mulholland named as his successor. These are some of the recent developments at Johnson & Johnson.
InvestingPro Insights
Johnson & Johnson's latest clinical trial results for its multiple myeloma treatment align well with the company's strong position in the pharmaceutical industry. According to InvestingPro data, J&J boasts a substantial market capitalization of $388.51 billion, underscoring its significant presence in the healthcare sector.
The company's focus on innovative therapies like TALVEY® and TECVAYLI® is reflected in its solid financial performance. J&J reported a revenue of $86.58 billion over the last twelve months, with a healthy revenue growth of 5.13%. This growth is particularly noteworthy given the company's size and maturity in the market.
InvestingPro Tips highlight J&J's financial stability and shareholder-friendly policies. The company has raised its dividend for 53 consecutive years, demonstrating a long-term commitment to returning value to shareholders. This is further supported by a current dividend yield of 3.07%, making it an attractive option for income-focused investors.
Moreover, J&J's stock is trading near its 52-week high, which could indicate market confidence in the company's recent developments and overall business strategy. The company's P/E ratio of 20.42 (adjusted for the last twelve months) suggests that investors are willing to pay a premium for J&J's earnings, possibly due to its strong market position and growth prospects in areas like multiple myeloma treatment.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips and insights. Currently, there are 11 more InvestingPro Tips available for Johnson & Johnson, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.